Patologia, objawy i leczenie choroby Parkinsona

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-397. doi:10.1016/S1474-4422(21)00030-2

Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223-222. doi:10.1176/jnp.14.2.223

Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442. doi:10.1212/wnl.17.5.427

Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819-824. doi:10.1136/jnnp.2006.103788

Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology. 1991;41(2 ( Pt 1)):168-173. doi:10.1212/wnl.41.2_part_1.168

Wender M, Pruchnik D, Kowal P, Florczak J, Zalejski M. Epidemiologia choroby Parkinsona w województwie poznańskim [Epidemiology of Parkinson disease in the Pozna'n province]. Przegl Epidemiol. 1989;43(2):150-155.

Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson's disease. Rev Neurol (Paris). 2016;172(1):14-26. doi:10.1016/j.neurol.2015.09.012

Hayes MT. Parkinson's Disease and Parkinsonism. Am J Med. 2019;132(7):802-807. doi:10.1016/j.amjmed.2019.03.001

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-844. doi:10.1002/mds.21956

Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615-1622. doi:10.1002/mds.25898

Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P. Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France. Mov Disord. 2018;33(9):1449-1455. doi:10.1002/mds.27447

Marino BLB, de Souza LR, Sousa KPA, et al. Parkinson's Disease: A Review from Pathophysiology to Treatment. Mini Rev Med Chem. 2020;20(9):754-767. doi:10.2174/1389557519666191104110908

Puschmann A. New Genes Causing Hereditary Parkinson's Disease or Parkinsonism. Curr Neurol Neurosci Rep. 2017;17(9):66. doi:10.1007/s11910-017-0780-8

Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674):1158-1160. doi:10.1126/science.1096284

Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference?. J Parkinsons Dis. 2019;9(3):501-515. doi:10.3233/JPD-191683

Winkler AS, Reuter I, Harwood G, Chaudhuri KR. The frequency and significance of 'striatal toe' in parkinsonism. Parkinsonism Relat Disord. 2002;9(2):97-101. doi:10.1016/s1353-8020(02)00010-x

Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci. 2017;18(3):551. Published 2017 Mar 4. doi:10.3390/ijms18030551

Cacabelos R, Torrellas C. Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response. Int J Mol Sci. 2015;16(12):30483-30543. Published 2015 Dec 21. doi:10.3390/ijms161226236

Lee A, Gilbert RM. Epidemiology of Parkinson Disease. Neurol Clin. 2016;34(4):955-965. doi:10.1016/j.ncl.2016.06.012

Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217-231. doi:10.1038/nrneurol.2017.27

Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19(2):170-178. doi:10.1016/S1474-4422(19)30287-X

Antony PM, Diederich NJ, Krüger R, Balling R. The hallmarks of Parkinson's disease. FEBS J. 2013;280(23):5981-5993. doi:10.1111/febs.12335

Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548-560. doi:10.1001/jama.2019.22360

Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376. doi:10.1136/jnnp.2007.131045

Cheng YH, Chou WC, Yang YF, et al. PBPK/PD assessment for Parkinson's disease risk posed by airborne pesticide paraquat exposure. Environ Sci Pollut Res Int. 2018;25(6):5359-5368. doi:10.1007/s11356-017-0875-4

James KA, Hall DA. Groundwater pesticide levels and the association with Parkinson disease. Int J Toxicol. 2015;34(3):266-273. doi:10.1177/1091581815583561

Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson's disease in rural California. Environ Health Perspect. 2009;117(12):1912-1918. doi:10.1289/ehp.0900852

Doria M, Maugest L, Moreau T, Lizard G, Vejux A. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease. Free Radic Biol Med. 2016;101:393-400. doi:10.1016/j.freeradbiomed.2016.10.008

de Queiroz Cavalcanti SA, de Almeida LA, Gasparotto J. Effects of a high saturated fatty acid diet on the intestinal microbiota modification and associated impacts on Parkinson's disease development. J Neuroimmunol. 2023;382:578171. doi:10.1016/j.jneuroim.2023.578171

Yang F, Wolk A, Håkansson N, Pedersen NL, Wirdefeldt K. Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts. Mov Disord. 2017;32(11):1631-1636. doi:10.1002/mds.27120

Erro R, Brigo F, Tamburin S, Zamboni M, Antonini A, Tinazzi M. Nutritional habits, risk, and progression of Parkinson disease. J Neurol. 2018;265(1):12-23. doi:10.1007/s00415-017-8639-0

Cheng P, Yu J, Huang W, et al. Dietary intake of iron, zinc, copper, and risk of Parkinson's disease: a meta-analysis. Neurol Sci. 2015;36(12):2269-2275. doi:10.1007/s10072-015-2349-0

Cicero CE, Mostile G, Vasta R, et al. Metals and neurodegenerative diseases. A systematic review. Environ Res. 2017;159:82-94. doi:10.1016/j.envres.2017.07.048

Logroscino G, Gao X, Chen H, Wing A, Ascherio A. Dietary iron intake and risk of Parkinson's disease. Am J Epidemiol. 2008;168(12):1381-1388. doi:10.1093/aje/kwn273

Kolahdouzan M, Hamadeh MJ. The neuroprotective effects of caffeine in neurodegenerative diseases. CNS Neurosci Ther. 2017;23(4):272-290. doi:10.1111/cns.12684

Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674-2679. doi:10.1001/jama.283.20.2674

Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol. 2013;106-107:17-32. doi:10.1016/j.pneurobio.2013.04.004

Raza C, Anjum R, Shakeel NUA. Parkinson's disease: Mechanisms, translational models and management strategies. Life Sci. 2019;226:77-90. doi:10.1016/j.lfs.2019.03.057

Barazzuol L, Giamogante F, Brini M, Calì T. PINK1/Parkin Mediated Mitophagy, Ca2+ Signalling, and ER-Mitochondria Contacts in Parkinson's Disease. Int J Mol Sci. 2020;21(5):1772. Published 2020 Mar 5. doi:10.3390/ijms21051772

Monzio Compagnoni G, Di Fonzo A, Corti S, Comi GP, Bresolin N, Masliah E. The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease. Mol Neurobiol. 2020;57(7):2959-2980. doi:10.1007/s12035-020-01926-1

Mustapha M, Mat Taib CN. MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies. Bosn J Basic Med Sci. 2021;21(4):422-433. Published 2021 Aug 1. doi:10.17305/bjbms.2020.5181

Li J, Yi M, Li B, et al. Polymorphism of neurodegeneration-related genes associated with Parkinson's disease risk. Neurol Sci. 2022;43(9):5301-5312. doi:10.1007/s10072-022-06192-8

Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and Pathogenesis of Parkinson's Syndrome. Annu Rev Pathol. 2023;18:95-121. doi:10.1146/annurev-pathmechdis-031521-034145

Yahalom G, Greenbaum L, Israeli-Korn S, et al. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. Parkinsonism Relat Disord. 2019;62:179-184. doi:10.1016/j.parkreldis.2018.12.014

Gao C, Liu J, Tan Y, Chen S. Freezing of gait in Parkinson's disease: pathophysiology, risk factors and treatments. Transl Neurodegener. 2020;9:12. Published 2020 Apr 15. doi:10.1186/s40035-020-00191-5

Pagano G, Ferrara N, Brooks DJ, Pavese N. Age at onset and Parkinson disease phenotype. Neurology. 2016;86(15):1400-1407. doi:10.1212/WNL.0000000000002461

Findley LJ, Gresty MA, Halmagyi GM. Tremor, the cogwheel phenomenon and clonus in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1981;44(6):534-546. doi:10.1136/jnnp.44.6.534

Mele B, Van S, Holroyd-Leduc J, Ismail Z, Pringsheim T, Goodarzi Z. Diagnosis, treatment and management of apathy in Parkinson's disease: a scoping review. BMJ Open. 2020;10(9):e037632. Published 2020 Sep 9. doi:10.1136/bmjopen-2020-037632

Abusrair AH, Elsekaily W, Bohlega S. Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies. Tremor Other Hyperkinet Mov (N Y). 2022;12:29. Published 2022 Sep 13. doi:10.5334/tohm.712

Dirkx MF, Bologna M. The pathophysiology of Parkinson's disease tremor. J Neurol Sci. 2022;435:120196. doi:10.1016/j.jns.2022.120196

Dirkx MF, Bologna M. The pathophysiology of Parkinson's disease tremor. J Neurol Sci. 2022 Apr 15;435:120196. doi: 10.1016/j.jns.2022.120196. Epub 2022 Feb 19. PMID: 35240491.

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease [published correction appears in Nat Rev Neurosci. 2017 Aug;18(8):509]. Nat Rev Neurosci. 2017;18(7):435-450. doi:10.1038/nrn.2017.62

Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med. 2012;366(6):511-519. doi:10.1056/NEJMoa1107911

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. doi:10.1002/mds.26424

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-397. doi:10.1016/S1474-4422(21)00030-2

Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683. doi:10.1001/jama.2014.3654

Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008;23 Suppl 3:S497-S508. doi:10.1002/mds.22028

LeWitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64-72. doi:10.1002/mds.26082

Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological Treatment of Tremor in Parkinson's Disease Revisited. J Parkinsons Dis. 2023;13(2):127-144. doi:10.3233/JPD-225060

Rinne UK. New strategies in the treatment of early Parkinson's disease. Acta Neurol Scand Suppl. 1991;136:95-98. doi:10.1111/j.1600-0404.1991.tb05028.x

Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. Neurologist. 2007;13(3):126-132. doi:10.1097/01.nrl.0000256433.15481.eb

Blackburn JK, Curry DW, Thomsen AN, Roth RH, Elsworth JD. Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism. Exp Neurol. 2020;327:113234. doi:10.1016/j.expneurol.2020.113234

Parsanejad M, Bourquard N, Qu D, et al. DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress. PLoS One. 2014;9(9):e106601. Published 2014 Sep 11. doi:10.1371/journal.pone.0106601

Morrow BA, Roth RH, Redmond DE Jr, Diano S, Elsworth JD. Susceptibility to a parkinsonian toxin varies during primate development. Exp Neurol. 2012;235(1):273-281. doi:10.1016/j.expneurol.2012.02.005

Elsworth JD. Parkinson's disease treatment: past, present, and future. J Neural Transm (Vienna). 2020;127(5):785-791. doi:10.1007/s00702-020-02167-1

Lindvall O, Hagell P. Role of cell therapy in Parkinson disease. Neurosurg Focus. 2002;13(5):e2. Published 2002 Nov 15. doi:10.3171/foc.2002.13.5.3

Lindvall O. Treatment of Parkinson's disease using cell transplantation. Philos Trans R Soc Lond B Biol Sci. 2015;370(1680):20140370. doi:10.1098/rstb.2014.0370

Morizane A, Kikuchi T, Hayashi T, et al. MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun. 2017;8(1):385. Published 2017 Aug 30. doi:10.1038/s41467-017-00926-5

Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 1997;275(5301):838-841. doi:10.1126/science.275.5301.838

Wang D, Li S, Gessler DJ, et al. A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Mol Ther Methods Clin Dev. 2018;9:234-246. Published 2018 Mar 16. doi:10.1016/j.omtm.2018.03.004